First Department of Cardiology, 'Hippokration' General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Endocrine Unit, 2nd Propaedeutic Department of Internal Medicine, School of Medicine, Research Institute and Diabetes Center, Attikon University Hospital, National and Kapodistrian University of Athens, 12641 Athens, Greece.
Int J Mol Sci. 2024 Oct 1;25(19):10595. doi: 10.3390/ijms251910595.
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease and is regarded as a liver manifestation of metabolic syndrome. It is linked to insulin resistance, obesity, and diabetes mellitus, all of which increase the risk of cardiovascular complications. Endothelial dysfunction (EnD) constitutes the main driver in the progression of atherosclerosis and coronary artery disease (CAD). Several pathophysiological alterations and molecular mechanisms are involved in the development of EnD in patients with NAFLD. Our aim is to examine the association of NAFLD and CAD with the parallel assessment of EnD, discussing the pathophysiological mechanisms and the genetic background that underpin this relationship. This review delves into the management of the condition, exploring potential clinical implications and available medical treatment options to facilitate the deployment of optimal treatment strategies for these patients.
非酒精性脂肪性肝病（NAFLD）是最常见的慢性肝病病因，被视为代谢综合征的肝脏表现。它与胰岛素抵抗、肥胖和糖尿病有关，所有这些都会增加心血管并发症的风险。内皮功能障碍（EnD）是动脉粥样硬化和冠状动脉疾病（CAD）进展的主要驱动因素。在患有 NAFLD 的患者中，有几种病理生理改变和分子机制涉及 EnD 的发展。我们的目的是检查 NAFLD 和 CAD 与 EnD 的平行评估之间的关联，讨论支持这种关系的病理生理机制和遗传背景。这篇综述深入探讨了该疾病的管理，探讨了潜在的临床意义和可用的治疗方法，以促进为这些患者部署最佳治疗策略。
